TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616850836
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules daily for 3-6 weeks before prostatectomy
Study: 36382431
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam (0.3 mg/kg, max 15 mg)
Study: 36335684
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg/day)
Study: 35241135
Drug: Neostigmine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (1 mg every 12 hours, increased to every 8 hours or every 6 hours depending on response)
Study: 36418088
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSNB) with glenohumeral joint (GHJ) injection and physiotherapy
Study: 36418088
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with glenohumeral joint (GHJ) injection and physiotherapy
Study: 38965031
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin therapy
Study: 34585554
Drug: LDL-C <
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C < 70 mg/dl
Study: 34585554
Drug: ACEI /
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI / ARB therapy
Study: 34330312
Drug: Ellagic acid
Normalized name: Ellagic acid
DrugBank: Ellagic acid (DB08846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ellagic acid (200 mg per day)
Study: 35255819
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy plus S. boulardii (Group S)
Study: 35255819
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy plus L. reuteri (Group P)
Study: 36201678
Drug: Informational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informational intervention emphasizing evidence-based harm reduction and treatment programs
Study: 35691460
Drug: PBRM (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBRM (15 mg/kg orally by gavage)
Study: 32075571
Drug: Primary intraventricular
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary intraventricular hemorrhage patients (combined treatment groups)
Study: 34407025
Drug: Integrated yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated yoga therapy (asanas and pranayama) from 18 to 22 weeks of gestation until delivery
Study: 32759258
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg two times per day
Study: 35180569
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (medication review, health education, adherence aids, seizure registration, therapeutic drug monitoring)
Study: 35180569
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program vs. Usual care
Study: 34976813
Drug: Single-agent sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent sodium cantharidinate (SCA)
Study: 34976813
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel (DOX)
Study: 34976813
Drug: Docetaxel/sodium cantharidinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/sodium cantharidinate combination (CON)
Study: 34976813
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (single-agent SCA and single-agent DOX)
Study: 35844809
Drug: Sublingual sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sufentanil 30 mcg
Study: 35844809
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 50 mcg
Study: 32756180
Drug: High-volume hemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume hemofiltration (HVHF), 24 hours continuous treatment, n = 21
Study: 35969887
Drug: Low-dose 17β
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 17β estradiol (n = 72)
Study: 32103495
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (TG1)
Study: 32103495
Drug: ω‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2)
Study: 36106652
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec (once-weekly basal insulin)
Study: 36106652
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 or U300 or insulin degludec (comparator treatments)
Study: 36106652
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U100 or U300 or insulin degludec
Study: 33464335
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase plus endovascular thrombectomy
Study: 32383767
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic capsules containing Lactobacillus paracasei LPC‐S01 (24 billion CFU)
Study: 32712606
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (4 sessions over 4-6 weeks)
Study: 36482786
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg acetaminophen
Study: 36482786
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg acetaminophen
Study: 32469182
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (6.4 mg/kg every 3 weeks)
Study: 32469182
Drug: Chemotherapy (physician's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (physician's choice, 55 received irinotecan and 7 paclitaxel)
Study: 35272017
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (100,000 IU monthly)
Study: 37549923
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine
Study: 32620335
Drug: Probiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (1 × 10^9 CFU/day, 2 capsules, tid) for 2 months
Study: 32102507
Drug: Serological noninvasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serological noninvasive screening and treatment for atrophic gastritis
Study: 36244364
Drug: Risdiplam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam (0.2 mg/kg for infants 5 months to 2 years, adjusted for younger infants)
Study: 32045540
Drug: New clinical
Normalized name: octinoxate 75 mg in 1 g / oxybenzone 40 mg in 1 g / avobenzone 20 mg in 1 g TOPICAL CREAM [Anew Clinical Absolute Even Spot Correcting Hand]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New clinical V̇O2 peak equation from 6MWT: V̇O2 peak (mL.kg‐1.min‐1) = (‐0.283*age(years)) ‐ (0.099*weight(kg)) + (0.071*6MWD(meters)) ‐(0.135*HR end(bpm)) + 22.789
Study: 32045540
Drug: New disease-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: New disease-specific V̇O2 peak equation from 6MWT: V̇O2 peak (mL.kg‐1.min‐1) = (‐0.236*age(years)) ‐ (0.094*weight(kg)) ‐(0.120*HR end(bpm)) + (0.067*6MWD(meters)) + (0.065*MVLPA(min/day)) ‐ (0.204*DT(years)) + 25.145
Study: 34275774
Drug: Drug holiday
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug holiday from 1 month before to 3 months after surgical tooth extraction
Study: 34275774
Drug: Drug continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug continuation
Study: 35893914
Drug: Oligomeric hyperproteic
Normalized name: procyanidolic oligomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomeric hyperproteic normocaloric (OHN) supplement
Study: 35893914
Drug: Immunonutritional (IN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutritional (IN) supplement
Study: 35791877
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg of caffeine during baseline night (BN)
Study: 35791877
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg of caffeine during total sleep deprivation (TSD)
Study: 35791877
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg of caffeine during BN
Study: 35791877
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg of caffeine during TSD
Study: 35015903
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (MTX)
Study: 32078436
Drug: Cocoa beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa beverage (15 g of cocoa and 75 mg of epicatechin daily)
Study: 36194164
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg, oral daily for a maximum of 1 year)
Study: 33812488
Drug: More-delayed strategy
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More-delayed strategy (RRT initiation postponed until mandatory indication or blood urea nitrogen concentration reached 140 mg/dL)
Study: 33285624
Drug: Focused shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shock wave therapy (FSWT)
Study: 35379064
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily for 2 weeks)
Study: 32196749
Drug: ABP 959
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP 959 (300 mg IV infusion)
Study: 35400328
Drug: Sacubitril/valsartan (97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (97/103 mg once or twice daily)
Study: 35400328
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg once or twice daily)
Study: 38267024
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (OAC)
Study: 33509129
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (10 mg three times per day)
Study: 32744483
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment and usual physical or psychological activities
Study: 35870990
Drug: S(+)‐ketamine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine hydrochloride injection
Study: 35870990
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without S(+)‐ketamine
Study: 35460601
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir (800 mg of darunavir plus 100 mg of ritonavir once daily)
Study: 35460601
Drug: Tenofovir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir (300 mg once daily) plus lamivudine (300 mg once daily)
Study: 35460601
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg twice daily) plus lamivudine (150 mg twice daily)
Study: 32756135
Drug: Extracorporeal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal shock-wave therapy (ESWT) - 3 sessions on the first, 14th, and 28th days
Study: 32756135
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone - 30 mg daily for 2 weeks, then 15 mg daily for another 2 weeks
Study: 35604613
Drug: Bilateral erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral erector spinae plane block using 20 ml of 0.375% ropivacaine on each side (ESPB group, n = 42)
Study: 32331018
Drug: Valbenazine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine (40 or 80 mg)
Study: 33747831
Drug: Digital educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital educational support group administered through WhatsApp Messenger
Study: 33201347
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg daily for 8 days
Study: 35218405
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg BUP (BUP16)
Study: 33232628
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: planned, structured follow-up telephone contact with the research nurse the day after discharge and then once weekly for 6 weeks
Study: 32611505
Drug: Afatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30 mg or 40 mg orally daily)
Study: 32611505
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 every 3 weeks × 4 cycles, followed by pemetrexed 500 mg/m2 every 3 weeks)
Study: 33530006
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a brief educational video on safe storage and disposal practices of unused opioid pills
Study: 35897080
Drug: Lidocaine-only injection
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine-only injection
Study: 34353223
Drug: Peri/postmenopausal women
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri/postmenopausal women with menopausal hormone therapy (MHT)
Study: 35080109
Drug: 0.125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg IV pimobendan
Study: 35080109
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg IV pimobendan
Study: 35080109
Drug: IV pimobendan
Normalized name: Pimobendan
DrugBank: Pimobendan (DB11450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pimobendan (both doses)
Study: 32390550
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in patients with prior OAC
Study: 32390550
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in patients without prior OAC
Study: 33417146
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once daily for 4 weeks (Group A; n = 32)
Study: 36473425
Drug: ARA 100
Normalized name: Seysara 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA 100 mg/kg and DHA 50 mg/kg
Study: 32785940
Drug: Immunotherapy (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (single agents and combinations)
Study: 36145087
Drug: Wagyu‐Cross beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wagyu‐Cross beef (120 g consumed four days/week for four weeks)
Study: 36145087
Drug: Commercial beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial beef (120 g consumed four days/week for four weeks)
Study: 35429946
Drug: Caffeine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (20 mg/kg initial dose, then 10 mg/kg daily maintenance)
Study: 34814657
Drug: Mud plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud plus bath therapy (group 1)
Study: 32891286
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy at -0.02 mpa
Study: 32891286
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy at -0.03 mpa
Study: 32891286
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy at -0.05 mpa
Study: 35124808
Drug: Preoperative high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative high-dose dexamethasone (1 mg/kg)
Study: 35523502
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT scan (LDCT)
Study: 34934009
Drug: Downward titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Downward titration of the level of pressure support (PSV)
Study: 34197338
Drug: Dog-Assisted Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-Assisted Therapy (DAT)
Study: 34298029
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg with Oxycodone 40 mg
Study: 34298029
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg with Oxycodone 40 mg
Study: 34298029
Drug: Oxycodone 40
Normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 40 mg alone
Study: 35129789
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation and medication review conducted by study pharmacists in addition to standard care
Study: 32950693
Drug: Defibrotide (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms)
Study: 32950693
Drug: Defibrotide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (25 mg/kg/day in phase 2 study)
Study: 36197920
Drug: modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified directly observed therapy (mDOT)
Study: 36197920
Drug: standard individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard individual therapy (SIT)
Study: 36197920
Drug: groups therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: groups therapy (GT)
Study: 34611892
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 150 mg once daily
Study: 34611892
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 75 mg once daily plus cilostazol 100 mg twice daily
Study: 34611892
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with ticagrelor 90 mg twice daily
Study: 34611892
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with clopidogrel 75 mg once daily (STD)
Study: 34611892
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (all combinations)
Study: 33849821
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (CC and HMG)
Study: 32138563
Drug: β-Alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Alanine (BA) supplementation (12 g·day‐1 for 14 days)
Study: 35377934
Drug: PDL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL injection and alternative palatal infiltration
Study: 35377934
Drug: Mock PDL
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock PDL injection and conventional palatal infiltration
Study: 33982892
Drug: Genetically determined
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically determined fasting insulin concentrations
Study: 33982892
Drug: Outlier-corrected fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outlier-corrected fasting insulin concentrations
Study: 33982892
Drug: Polygenic scores
Normalized name: polygalic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygenic scores for fasting insulin
Study: 35199478
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of esaxerenone and SGLT2 inhibitor
Study: 38874618
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor
Study: 34221093
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (opioid analgesics) with no additional interventions
Study: 34312190
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (sublingual or oral) at 50, 100 or 200 mg daily over 3 days
Study: 34312190
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (oral vs sublingual)
Study: 34426064
Drug: Monthly group‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group‐based diabetes self‐management education (DSME) and monthly vouchers ($28‐$140/month) redeemable for fruits and vegetables at local markets
Study: 32987647
Drug: Colostrum (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum (2 × 500 mg) harvested at 2 hours after delivery
Study: 32987647
Drug: Colostrum (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum (2 × 500 mg) harvested at 24 hours after delivery
Study: 32987647
Drug: Colostrum (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum (2 × 500 mg) harvested at 72 hours after delivery
Study: 34287475
Drug: Dengzhan Shengmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhan Shengmai capsule 0.36 g three times a day
Study: 34287475
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride 5 mg once a day
Study: 34596269
Drug: Low-dose intramuscular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intramuscular testosterone treatment (1 mg/kg/month)
Study: 34596269
Drug: Per oral
Normalized name: Amino Acids/Copper Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per oral letrozole treatment (2.5 mg/day)
Study: 33064410
Drug: Hormones with
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormones with left eye pupil constriction difference